New Purchase Includes Ten HiSeq 2000®Systems, HiSeq 2500® Upgrades, and Two MiSeq®Systems
SAN DIEGO--(BUSINESS WIRE)--Mar. 22, 2012-- Illumina (NASDAQ:ILMN) today announced that Macrogen, Inc., a global sequencing services company based in Korea, purchased an additional ten Illumina HiSeq 2000 systems and two MiSeq systems, as well as HiSeq 2500 upgrades. This strategic scale-up expands Macrogen’s capacity with Illumina’s sequencing systems and will be completed by the end of 2012.
“Macrogen’s decision to significantly increase their sequencing capacity is further validation that Illumina is the platform of choice for sequencing service providers,” said Tim Orpin, Vice President of Illumina’s Asia Pacific Region. “HiSeq and MiSeq systems deliver state-of-the-art performance with unmatched daily output, reliability, and ease of use. Illumina and Macrogen have built a strong collaborative relationship, and the new investment will support Macrogen’s efforts to transform medical genomics in Asia and the rest of the world.”
Professor Jeong-Sun Seo, Chairman of Macrogen, added, “Our vision is to improve quality of life by enhancing understanding of the human genome, and to be a global leader in providing genome sequencing services, towards the ultimate goal of personalized medicine. As part of these efforts, we launched a premium global sequencing service, Axeq, in 2011.”
Macrogen is also collaborating with researchers and physicians to identify novel targets for disease genes, and identified a fusion gene, KIF5B-RET, from a non-smoking lung cancer patient last year.
“We are very excited about this new finding and other discoveries being enabled by next generation sequencing,” said Dr. Hyungtae Kim, CEO of Macrogen. “Our goal is to develop diagnostic tests on the MiSeq platform, and the upgrades to HiSeq 2500 will give us the ability to sequence whole human genomes on one machine in a day. This is critical to providing the turnaround time required for clinical samples. We also want the ability to combine HiSeq and MiSeq data, to save time and cost, and ultimately to provide the best service to our customers.”
About Illumina
Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.
About Macrogen
Macrogen, Inc. (www.macrogen.com), based in Seoul, Korea, is a world leading service provider in high-quality gene analysis and has enjoyed stable and steady growth since 1997. The company’s diverse offerings include DNA sequencing, next generation sequencing, microarray analysis, oligonucleotide synthesis, and genetically engineered mice services. In addition, Macrogen has been expanding its business scope into other areas such as molecular diagnostics and consumer genomics. With a global presence, Macrogen operates through U.S. subsidiaries in Rockville, New York, and Cambridge; in the Netherlands in Europe; and, in Tokyo, Japan. Macrogen is listed on the Korea Securities Dealers Automated Quotation (ticker symbol: A038290).
Forward-Looking Statements
This release contains forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.
Source: Illumina, Inc.
Illumina, Inc.
Investors:
Kevin Williams, MD
Investor Relations
858-332-4989
kwilliams@illumina.com
or
Media:
Jennifer Temple
Public Relations
858-429-8350
pr@illumina.com
